U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07840443) titled 'Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma' on Sept. 18.
Brief Summary: This is a window of opportunity study designed to provide short duration exposure to camizestrant prior to planned curative intent surgery, with the anticipated benefit of demonstrating target engagement and suppression of ER signalling in ER positive endometrial cancer without delaying standard surgical management.
Study Start Date: Oct. 26
Study Type: INTERVENTIONAL
Condition:
Estrogen Receptor-positive
Early Stage Endometrial Cancer
Intervention:
DRUG: Camizestrant
Camizestrant is an oral selective ER antagonist and degrad...